The DCVax-Direct trial is unblinded, but patient status has not been disclosed by either NWBO or MD Anderson. Thus, any purchases made by management would qualify under the "Insider Trading" as they are well aware of the current success rate of DCVax-Direct.
In addition, they are in pricing negotiations with the Germany Sickness Fund. That is also non-public information.
Your previous comment clearly implies that this stock is a POS because NWBO management is not buying. Yet you seem to understand that buying during this time period would pose significant legal and regulatory risks. So not sure what your point is.